by CN Bio. | Apr 26, 2022 | NASH, Press releases
First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and efficiency of NASH drug discovery Cambridge, UK, 26 April 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that...
by CN Bio. | Apr 21, 2021 | NASH
Liver disease is a serious worldwide problem linked to approximately two million deaths per year and in many cases is entirely preventable (Sumeet et al, 2019). One of the most common causes of chronic liver disease is non-alcoholic fatty liver disease (NAFLD), which...
by CN Bio. | Jan 27, 2021 | NASH
Obesity is a global epidemic. Up to a third of the USA’s adult population is now obese and worldwide, the prevalence of obesity has almost tripled since the 1970s. Increased obesity has triggered a wave of serious associated health conditions, notably cardiovascular...
